Bristol-Myers Squibb Company Credit Rating

Sonuçlar 1 - 50 Ve 146

Sayfa Ve 3 Next

şununla filtrele:

Tarih	Belge Türü	Başlık	Kaynak
14 Feb 2024	Rating Action	Moody's assigns A2 rating to Bristol-Myers Squibb's sr. notes; outlook is negative	Moody's Investors Service
13 Feb 2024	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis after confirmation of ratings with a negative outlook	Moody's Investors Service
12 Feb 2024	Rating Action	Moody's confirms Bristol-Myers Squibb at A2; outlook is negative	Moody's Investors Service
27 Dec 2023	Credit Opinion	Bristol-Myers Squibb Company: Update following ratings under review for downgrade	Moody's Investors Service
22 Dec 2023	Rating Action	Moody's places Bristol-Myers Squibb's ratings under review for downgrade	Moody's Investors Service
24 Nov 2023	Peer Snapshot	Bristol-Myers Squibb Company - September 2023 (LTM): Peer Snapshot	Moody's Investors Service
30 Oct 2023	Rating Action	Moody's assigns A2 ratings to Bristol's sr. notes; stable outlook	Moody's Investors Service
10 Oct 2023	Announcement	Moody's: Bristol's acquisition of Mirati adds approved cancer drug and pipeline opportunities but adds execution risk	Moody's Investors Service
10 Oct 2023	Issuer Comment	Bristol-Myers Squibb Company: Acquisition of Mirati adds approved cancer drug and pipeline opportunities, but adds execution risk	Moody's Investors Service
30 Aug 2023	Peer Snapshot	Bristol-Myers Squibb Company - June 2023 (LTM): Peer Snapshot	Moody's Investors Service
27 Jul 2023	Credit Opinion	Bristol-Myers Squibb Company: Revlimid erosion steepens, but new products are steadily growing	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
11 Jul 2023	Issuer Profile	Bristol-Myers Squibb Company: Key facts and statistics - LTM March 2023	Moody's Investors Service
23 Jun 2023	Peer Snapshot	Bristol-Myers Squibb Company - March 2023 (LTM): Peer Snapshot	Moody's Investors Service
11 Apr 2023	Peer Snapshot	Bristol-Myers Squibb Company - December 2022 (LTM): Peer Snapshot	Moody's Investors Service
27 Jan 2023	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis – new launches underway to prepare for 2026-2028 patent cliff	Moody's Investors Service
16 Dec 2022	Peer Snapshot	Bristol-Myers Squibb Company - September 2022 (LTM): Peer Snapshot	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
27 Sep 2022	Peer Snapshot	Bristol-Myers Squibb Company - June 2022 (LTM): Peer Snapshot	Moody's Investors Service
04 Aug 2022	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis – ongoing M&A is supported by robust cash flow	Moody's Investors Service
13 Jun 2022	Peer Snapshot	Bristol-Myers Squibb Company - March 2022 (LTM): Peer Snapshot	Moody's Investors Service
09 Mar 2022	Peer Snapshot	Bristol-Myers Squibb Company - December 2021 (LTM): Peer Snapshot	Moody's Investors Service
15 Feb 2022	Rating Action	Moody's assigns A2 to Bristol-Myers notes; stable outlook	Moody's Investors Service
04 Feb 2022	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis – growth will slow as Revlimid generics begin, but robust cash flow will continue	Moody's Investors Service
18 Nov 2021	Peer Snapshot	Bristol-Myers Squibb Company - September 2021 (LTM): Peer Snapshot	Moody's Investors Service
10 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company	Moody's Investors Service
05 Aug 2021	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis – robust cash flow will help company prepare for 2026-2027 patent cliff	Moody's Investors Service
01 Jun 2021	Peer Snapshot	Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot	Moody's Investors Service
18 Mar 2021	Peer Snapshot	Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot	Moody's Investors Service
05 Feb 2021	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis following outlook revision to stable from negative	Moody's Investors Service
04 Feb 2021	Rating Action	Moody's affirms Bristol's A2 rating; revises outlook to stable	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company	Moody's Investors Service
01 Dec 2020	Peer Snapshot	Bristol-Myers Squibb Company - September 2020 (LTM): Peer Snapshot	Moody's Investors Service
09 Nov 2020	Rating Action	Moody's assigns A2 to Bristol-Myers' sr. notes; outlook negative	Moody's Investors Service
06 Oct 2020	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis - MyoKardia deal delays deleveraging but provides long-term revenue potential	Moody's Investors Service
05 Oct 2020	Rating Action	Moody's affirms Bristol-Myers at A2; outlook remains negative	Moody's Investors Service
01 Sep 2020	Peer Snapshot	Bristol-Myers Squibb Company - June 2020 (LTM): Peer Snapshot	Moody's Investors Service
01 Jun 2020	Peer Snapshot	Bristol-Myers Squibb Company - March 2020 (LTM): Peer Snapshot	Moody's Investors Service
08 May 2020	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis - credible deleveraging plan despite temporary coronavirus pressures	Moody's Investors Service
14 Apr 2020	Announcement	Moody's corrects the rating on CUSIP 110122BD9	Moody's Investors Service
19 Mar 2020	Peer Snapshot	Bristol-Myers Squibb Company - December 2019 (LTM): Peer Snapshot	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company	Moody's Investors Service
06 Dec 2019	Rating Action	Moody's upgrades Celgene to A3	Moody's Investors Service
20 Nov 2019	Peer Snapshot	Bristol-Myers Squibb Company - September 2019 (LTM): Peer Snapshot	Moody's Investors Service
08 Nov 2019	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis following rating confirmation	Moody's Investors Service
07 Nov 2019	Rating Action	Moody's confirms Bristol-Myers Squibb at A2; negative outlook	Moody's Investors Service
24 Sep 2019	Announcement	Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023	Moody's Investors Service
19 Aug 2019	Peer Snapshot	Bristol-Myers Squibb Company - June 2019 (LTM): Peer Snapshot	Moody's Investors Service
08 Jul 2019	Credit Opinion	Bristol-Myers Squibb Company: Update to credit analysis - Celgene acquisition pending, but now excludes Otezla	Moody's Investors Service
24 Jun 2019	Announcement	Moody's: Bristol's Otezla divestiture credit negative	Moody's Investors Service

Sonuçlar 1 - 50 Ve 146

Sayfa Ve 3 Next

Araştırmalar & Notlar

Ürünler & Çözümler

Haberler & Etkinlikler

Kayıtlı Kullanıcı

Daha kaydolmadınız mı?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: